Billy Evans, partner of Theranos founder Elizabeth Holmes, unveils Haemanthus, a startup aiming to revolutionize health optimization through advanced blood testing. With ambitions to raise over $50 million, this venture echoes Theranos' controversial legacy. Is it a groundbreaking innovation or a repeat of past mistakes?
A groundbreaking urine test for prostate cancer has shown remarkable accuracy, outperforming traditional blood tests. Set to enter clinical trials, this innovation may make routine screenings a reality, potentially saving thousands of lives.
